Beijing Leadman Biochemistry Co.,Ltd.

Equities

300289

CNE100001C22

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4.31 CNY -3.36% Intraday chart for Beijing Leadman Biochemistry Co.,Ltd. +4.87% -29.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Leadman Biochemistry Co.,Ltd. Proposes Final Cash Dividend for 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Leadman Biochemistry Unit Obtains Shanghai Clearance for Fatty Acid Kit MT
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shenzhen Uni-medica Technology Co., Ltd. announced that it has received CNY 20 million in funding from Beijing Leadman Biochemistry Co.,Ltd. CI
Shenzhen Uni-medica Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Beijing Leadman Biochemistry Co.,Ltd. CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Beijing Leadman Biochemistry Co.,Ltd. Approves Cash Dividend for the Year 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Proposes Final Dividend for the Year 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Approves Board Appointments CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Beijing Yongtai Enter into the Lease Agreement with Beijing Leadman Biochemistry Co.,Ltd CI
Beijing Leadman Biochemistry : Raises $85 Million From Private Share Sale; Shares Rise Nearly 3% MT
Beijing Leadman Biochemistry Co.,Ltd. announced that it has received CNY 556.6 million in funding from Guangzhou GET Technologies Development Co., Ltd CI
Beijing Leadman Biochemistry Co.,Ltd. Announces Earnings Results for the Half Year Ended June 30, 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the First quarter Ended March 31, 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Beijing Leadman Biochemistry Co.,Ltd. Announces Dismissal of Luo Haobo as a Director CI
Chart Beijing Leadman Biochemistry Co.,Ltd.
More charts
Beijing Leadman Biochemistry Co., Ltd is a China-based company principally engaged in the research, development, production and sales of in-vitro diagnostic reagents. Its diagnostic reagents include chemiluminescence diagnostic reagents and biochemical diagnostic agents, such as hepatitis B virus attributes and tumor markers. The Company also produces diagnostic instruments and biochemical raw materials. Its diagnostic instruments include automatic luminescence immunity analyzers, among others. Its products are applied in various fields, including liver diseases, kidney diseases, cardiovascular diseases, immunological diseases and diabetes, among others. The Company mainly operates businesses in domestic market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300289 Stock
  4. News Beijing Leadman Biochemistry Co.,Ltd.
  5. Beijing Leadman Biochemistry : Raises $85 Million From Private Share Sale; Shares Rise Nearly 3%